From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of breast cancer have been updated for 2022 and include two important changes involving neratinib (NERLYNX®). The first update added NERLYNX to the body of the guidelines for the treatment of adjuvant …
Clinical trial demonstrates focused ultrasound can deliver antibody therapy to breast cancer metastases in the brain
By: Focused Ultrasound Foundation From: medicalxpress.com In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto, Canada, have demonstrated that magnetic resonance (MR)-guided focused ultrasound can be used to safely deliver antibody therapy to breast cancer that has metastasized to the brain. In this Phase I clinical trial for Her2-positive breast cancer patients, the Sunnybrook team captured …
Could Your Patient Benefit? New Clinical Trials in Breast Cancer
By: Helen Leask From: medscape.com A number of phase 3 studies in breast cancer have opened in recent months. Maybe one of your patients could benefit from being enrolled? Advanced HER2+ breast cancer. Patients with previously treated advanced or metastatic HER2+ breast cancer with and without brain metastases are sought for the DESTINY-B12 trial of trastuzumab deruxtecan (Enhertu). Patients will …
New Drug Combo Boosts Survival Against Aggressive Form of Breast Cancer
By: Denise Mann, HealthDay Reporter From: webmd.com New research offers good news for women with an aggressive HER2-positive breast cancer. A targeted therapy, trastuzumab deruxtecan (T-DXd), sold as Enhertu, triples the length of time that the cancer remains in check when compared with the current gold standard, trastuzumab emtansine (T-DM1). Both of these drugs are second-line treatment options for HER2-positive …
Third-Line Treatment Data for HER2+ Advanced Breast Cancer
By: Sara Hurvitz, MD, Steven Vogl, MD From: cancernetwork.com Sara Hurvitz, MD: Welcome to CancerNetwork® Between the Lines. We are going to be reviewing a Journal Club experience titled “Third-Line Treatment of HER2-Positive Advanced Breast Cancer: From No Standard to a Pandora’s Box.” My name is Dr Sara Hurvitz. I’m a breast cancer medical oncologist practicing at the University of …
Enhertu improves survival in Phase III breast cancer trial
From: europeanpharmaceuticalreview.com Enhertu (trastuzumab deruxtecan) significantly improved survival in the DESTINY-Breast03 Phase III head-to-head trial against trastuzumab emtansine. Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial has shown that Enhertu (trastuzumab deruxtecan) demonstrates superiority over trastuzumab emtansine (T-DM1) in treating HER2-positive metastatic breast cancer. Enhertu is an HER2-directed antibody drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo, …
KAMILLA Data Reinforce Favorable Benefit/Risk Profile of T-DM1 in HER2+ Breast Cancer
By: Ryan Scott From: onclive.com Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent. Data from the phase 3 KAMILLA trial (NCT01702571) confirm the safety and efficacy of ado-trastuzumab emtansine (T-DM1, Kadcyla) that had previously been observed in patients with previously …
Real-world effectiveness may not reflect trial efficacy for HER2-targeted agents
By: Laura Cowen From: medwirenews.com Women receiving first-line pertuzumab or second-line trastuzumab emtansine (T-DM1) for HER2-positive metastatic breast cancer have lower than expected survival times in clinical practice when compared with pivotal trials, researchers report. Writing in JAMA Oncology, Josee-Lyne Ethier (Queen’s University, Kingston, Ontario, Canada) and co-authors suggest that the “differences in outcome likely reflect differences in patient population …
Therapeutic target discovery could improve breast cancer treatments
By: Anna Begley From: drugtargetreview.com Research by a team in Canada reveals a promising therapeutic target to counter HER2-positive breast cancer. New research by a team at Université de Montréal (UdeM), Canada, has revealed a highly promising therapeutic target that could lead to better treatments of HER2-positive breast cancer. In this breast cancer, a gene called HER2 is expressed, promoting …
Promising new research on aggressive breast cancer
Source: University of Montreal From: eurekalert.org Better treatments of HER2-positive breast cancer are closer at hand, thanks to new research by a team led by Université de Montréal professor Jean-François Côté at the cytoskeleton organization and cell-migration research unit of the UdeM-affiliated Montreal Clinical Research Institute. Published in PNAS, the journal of the U.S. National Academy of Sciences, the new …